Based in Calgary, Alberta, with labs in Burnaby, British Columbia, and Mountain View, California, the company is focussing on advancing its yeast strain to produce ultra-pure, pharmaceutical grade CBD, for the treatment for pain, anxiety, obesity, brain disorders, among other significant indications.
Additional Information:
Video Transcript:
I’m Fiona Forbes for Investmentpitch Media
Willow Biosciences (CSE:WLLW) has received conditional approval from the Toronto Stock Exchange to list its common shares on the TSX.
Upon listing, the company will voluntarily delist from the Canadian Securities Exchange.
Trevor Peters, President and CEO, stated: "Listing on the TSX is a significant milestone for Willow. The TSX will broaden our investment appeal and leave us well positioned to execute on our strategic initiatives for 2020 and beyond. We are excited to add this to our 2019 accomplishments for Willow, which has seen us complete a go-public transaction, raise $37 million in a private placement and subsequent warrant exercise, enter into a potentially game-changing strategic partnership with Noramco, Inc., build out three state-of-the-art laboratories and continue to advance our cannabidiol producing yeast strain towards scale-up expected in the first half of 2020. Willow is uniquely positioned as one of the few public pure-play synthetic biology companies in the world targeting the potentially massive consumer packaged goods and pharmaceutical industries and being listed on the TSX helps to increase our exposure to global investors."
Based in Calgary, Alberta, with labs in Burnaby, British Columbia, and Mountain View, California, the company is focussing on advancing its yeast strain to produce ultra-pure, pharmaceutical grade CBD, for the treatment for pain, anxiety, obesity, brain disorders, among other significant indications.
Willow's science team has a proven track record of developing manufacturing technologies for high purity compounds in pain and cancer treatments.
The company’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life changing drugs.
The company has an exclusive partnership with Noramco to jointly develop and commercialize CBD
produced through biosynthesis.
During the past quarter, the company expanded its research and development team to 33 technical staff, including 21 Ph.D. level scientists, consisting of plant scientists, strain engineers, analytical chemists and fermentation process engineers, across all three sites.
The plant sciences team in Canada continues to advance its understanding of cannabinoid accumulation in C. sativa along with translation of these results in its yeast production host.
These results are further complemented by the high-throughput strain engineering capabilities in the San Francisco Bay Area labs to expand upon beneficial genetic diversity and further optimize the company’s yeast strain toward commercial targets.
As a result of these combined efforts, the company has increased cannabinoid production by 25-fold and identified hundreds of beneficial genetic changes that will provide additional increases.
These improved strains are now undergoing evaluation in fermentation tanks at the company’s development partner's facilities.
At the current trajectory, management anticipates delivering a strain for scale up development starting in the first half of 2020.
The shares of Willow Biosciences, which started trading on the Canadian Securities Exchange on April 15th, are currently trading at $0.65.
For more information, please visit the company’s website www.willowbio.com, contact Trevor Peters, President & CEO at 403-669-4848 or email t.peters@willowbio.com or Troy Talkkari, VP Corporate Development, at 403-618-1117 or by email at t.talkkari@willowbio.com.
I’m Fiona Forbes for Investmentpitch Media
